drugset / Trial / NCT06891560
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Phase 2
Recruiting
34 enrolled
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).
Timeline
- Start
- 2025-03-31
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enfortumab Vedotin | Other / unclassified | — | Intravenous |